194 related articles for article (PubMed ID: 29279943)
1. Assessment of alteration in liver
Salomon T; Nganoa C; Gac AC; Fruchart C; Damaj G; Aide N; Lasnon C
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):941-950. PubMed ID: 29279943
[TBL] [Abstract][Full Text] [Related]
2. Interobserver Agreement of Interim and End-of-Treatment
Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
[TBL] [Abstract][Full Text] [Related]
3. Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?
Enilorac B; Lasnon C; Nganoa C; Fruchart C; Gac AC; Damaj G; Aide N
J Nucl Med; 2018 Jul; 59(7):1049-1055. PubMed ID: 29242403
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
5. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
6. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
Toledano MN; Vera P; Tilly H; Jardin F; Becker S
PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
[TBL] [Abstract][Full Text] [Related]
7. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
8. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.
Eertink JJ; Arens AIJ; Huijbregts JE; Celik F; de Keizer B; Stroobants S; de Jong D; Wiegers SE; Zwezerijnen GJC; Burggraaff CN; Boellaard R; de Vet HCW; Hoekstra OS; Lugtenburg PJ; Chamuleau MED; Zijlstra JM;
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):943-952. PubMed ID: 34476551
[TBL] [Abstract][Full Text] [Related]
9. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.
Bouard L; Bodet-Milin C; Bailly C; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Mahé B; Dubruille V; Blin N; Touzeau C; Gastinne T; Lok A; Bonnet A; Béné MC; Gouill SL; Moreau P; Kraeber-Bodéré F; Chevallier P
Biol Blood Marrow Transplant; 2019 May; 25(5):906-911. PubMed ID: 30481598
[TBL] [Abstract][Full Text] [Related]
10. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
11. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
13. End-of-treatment
Allioux F; Gandhi D; Vilque JP; Nganoa C; Gac AC; Aide N; Lasnon C
Leuk Lymphoma; 2021 Dec; 62(12):2890-2898. PubMed ID: 34219589
[TBL] [Abstract][Full Text] [Related]
14. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
15. Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography.
Wang L; Zhang S; Xin J
Quant Imaging Med Surg; 2023 Oct; 13(10):6789-6800. PubMed ID: 37869355
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
[TBL] [Abstract][Full Text] [Related]
17. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
[TBL] [Abstract][Full Text] [Related]
18. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
19. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
20. Interim PET in Diffuse Large B-Cell Lymphoma.
Kurch L; Hüttmann A; Georgi TW; Rekowski J; Sabri O; Schmitz C; Kluge R; Dührsen U; Hasenclever D
J Nucl Med; 2021 Aug; 62(8):1068-1074. PubMed ID: 33246974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]